LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback